Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
8.83
+0.78 (9.69%)
Nov 21, 2024, 1:44 PM EST - Market open
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending September 30, 2024, a decrease of -98.62%. This brings the company's revenue in the last twelve months to $52.00K, down -81.36% year-over-year. In the year 2023, Altimmune had annual revenue of $426.00K, down -726.47%.
Revenue (ttm)
$52.00K
Revenue Growth
-81.36%
P/S Ratio
n/a
Revenue / Employee
$881
Employees
59
Market Cap
628.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
| Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Auna S.A. | 1.10B |
| Pharming Group | 285.75M |
| Talkspace | 181.29M |
| SI-BONE | 157.04M |
| Mereo BioPharma Group | 1.00M |
| PureTech Health | 468.00K |
| Opthea | 261.86K |
ALT News
- 6 days ago - Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - GlobeNewsWire
- 7 days ago - Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge - Seeking Alpha
- 8 days ago - Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health - Seeking Alpha
- 9 days ago - Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - GlobeNewsWire
- 14 days ago - Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - GlobeNewsWire
- 15 days ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire